05 January 2026
05 January 2026
NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple sclerosis.
Under the terms, Insilico will receive up to $32m in upfront and near-term research payments.
The agreement termination comes only a year after the two companies started working together.
The ONS-5010 BLA resubmission was supported by data from the NORSE programme, including NORSE TWO and other trials.
The approval marks the first new pharmacologic treatment in motion sickness in over four decades.
Byooviz received approval from the European Commission in August 2021 as a single-use intravitreal vial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
